The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.
Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
SARS-CoV-2 Associated With Increased Incidence of Psoriasis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Discovering Last Month's Psoriasis Spotlight
Jeremy Brauer, MD, Publishes Men’s Aesthetics Textbook